Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology therapeutics company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will present on Monday, September 8, 2025, at 9:30 am ET.

Investors can access the presentation through a live webcast available on Verrica's website, with a replay available for 90 days following the event.

News Market Reaction

-4.38%

1 alert

-4.38% News Effect

On the day this news was published, VRCA declined 4.38%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27^th Annual Global Investment Conference in New York City.

H.C. Wainwright 27^th Annual Global Investment Conference, September 8-10, 2025
Event details:
Date: Monday, September 8, 2025
Time: 9:30 am ET
Location: New York, New York

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.  For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

When is Verrica Pharmaceuticals (VRCA) presenting at the H.C. Wainwright Conference?

Verrica Pharmaceuticals will present on Monday, September 8, 2025, at 9:30 am ET in New York City.

Who will be presenting for Verrica Pharmaceuticals at the H.C. Wainwright Conference?

Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the conference.

How can investors access Verrica Pharmaceuticals' H.C. Wainwright Conference presentation?

Investors can access the presentation via a live webcast through Verrica's website at www.verrica.com in the Investors/Presentations & Events section.

How long will the replay of Verrica Pharmaceuticals' presentation be available?

The webcast replay will be available for 90 days following the event on Verrica's website.